CSTL Q3 2022 Earnings — Castle Biosciences, Inc. Revenue & Financial Results | Market Cap Arena

CSTLCastle Biosciences, Inc.

$805M

Q3 2022 Earnings

Healthcare Medical - Diagnostics & Research

Income Statement

Revenue

$37M+57.7% YoY

Gross Profit

$28M76.1% margin

Operating Income

-$22M-58.2% margin

Net Income

-$20M-54.7% margin

EPS (Diluted)

$-0.77

QoQ Revenue Growth

+6.2%

Cash Flow

Operating Cash Flow

-$5M

Free Cash Flow

-$7M

Stock-Based Comp.

$9M

Balance Sheet

Total Assets

$458M

Total Liabilities

$46M

Stockholders' Equity

$411M

Cash & Equivalents

$134M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$37M	$23M	+57.7%
Gross Profit	$28M	$19M	+48.4%
Operating Income	-$22M	-$12M	-82.3%
Net Income	-$20M	-$12M	-71.7%

Revenue Segments

Dermatologic

$34M92%

Service, Other

$3M8%